Elanco Animal Health (NYSE:ELAN) Director Acquires $936,000.00 in Stock

Elanco Animal Health Incorporated (NYSE:ELAN) Director Lawrence Erik Kurzius bought 40,000 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The stock was purchased at an average cost of $23.40 per share, with a total value of $936,000.00. Following the acquisition, the director directly owned 188,647 shares in the company, valued at $4,414,339.80. This trade represents a 26.91% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Elanco Animal Health Trading Up 0.3%

Shares of ELAN stock opened at $24.05 on Monday. Elanco Animal Health Incorporated has a 52-week low of $17.11 and a 52-week high of $27.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. The firm has a market capitalization of $12.02 billion, a PE ratio of -58.66, a PEG ratio of 1.44 and a beta of 1.67. The stock has a fifty day simple moving average of $24.56 and a two-hundred day simple moving average of $24.00.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.07. The firm had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The firm’s revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the business posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, analysts predict that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. TD Cowen lifted their price objective on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. KeyCorp upped their target price on shares of Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. raised their target price on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Morgan Stanley lifted their price target on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Wednesday, July 22nd. Finally, Citigroup boosted their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $29.09.

Institutional Investors Weigh In On Elanco Animal Health

Several large investors have recently added to or reduced their stakes in ELAN. BlackRock Inc. purchased a new position in shares of Elanco Animal Health in the 2nd quarter worth approximately $1,202,198,000. Primecap Management Co. CA bought a new position in shares of Elanco Animal Health during the 2nd quarter valued at approximately $1,118,402,000. The Manufacturers Life Insurance Company purchased a new stake in Elanco Animal Health during the 2nd quarter valued at $205,636,000. UBS Group AG raised its holdings in Elanco Animal Health by 56.7% during the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after buying an additional 5,961,457 shares during the period. Finally, Sei Investments Co. raised its holdings in Elanco Animal Health by 737.5% during the 1st quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock valued at $135,214,000 after buying an additional 4,975,721 shares during the period. 97.48% of the stock is owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.